Changes__O in__O the__O industry__O Thornalley__B-MISC presented__O his__O findings__O regarding__O protein__O damage__O with__O first-generation__O PD__B-ORG fluids__O and__O improved__O clinical__O outcomes__O with__O low-GDP__O PD__B-ORG fluids__O at__O several__O international__O meetings,__O including__O the__O 5th__O EuroPD__B-ORG conference__O in__O 2002,__O the__O American__B-ORG Society__I-ORG Nephrology__I-ORG Annual__I-ORG Renal__I-ORG Week__O meetings__O in__O 1999,__O 2002,__O and__O 2005,__O and__O the__O 12th__O Congress__B-ORG of__O the__O International__B-ORG Society__I-ORG for__O Peritoneal__B-ORG Dialysis__I-ORG in__O 2008.__O
These__O meetings__O are__O attended__O by__O representatives__O from__O the__O major__O global__O manufacturers__O of__O dialysis__O fluids,__O including__O Baxter__B-ORG Healthcare,__I-ORG Gambro__I-ORG AB__I-ORG (part__O of__O Baxter__B-ORG Healthcare__I-ORG from__O 2013)__O and__O Frenesius.__O
With__O funding__O from__O Baxter__B-ORG Healthcare,__I-ORG Cancer__I-ORG Research__I-ORG UK,__I-ORG Dynamis__I-ORG Therapeutics__I-ORG Inc.,__I-ORG Fresenius__I-ORG Medical__I-ORG Care__I-ORG AG,__I-ORG Gambro__I-ORG AB,__I-ORG GlaxoSmithKline,__I-ORG TransGenic__I-ORG Inc.,__I-ORG Woerwag__I-PER Pharma,__I-PER and__O Chroma__B-PER Therapeutics,__I-PER Thornalley__I-PER organized__O a__O colloquium__O on__O GDP__O researcha__O (entitled__O "Enzymatic__O defence__O against__O glycation__O in__O health,__O disease__O and__O therapeutics"),__O which__O was__O presented__O at__O the__O 679th__O Meeting__O of__O the__O Biochemical__B-ORG Society__I-ORG held__O in__O Colchester__B-LOC in__O 2003.__O
Approximately__O 100__O clinicians,__O industry__O researchers__O and__O academics__O attended__O the__O colloquium.__O
From__O 2002__O onwards,__O in__O light__O of__O the__O data__O presented__O by__O Thornalley,__O major__O manufacturers__O of__O PD__B-ORG fluids,__O including__O Baxter__B-ORG Healthcare,__I-ORG Gambro__I-ORG AB,__I-ORG and__O Fresenius__B-ORG Medical__I-ORG Care__I-ORG AG,__I-ORG developed__O second-generation__O and__O third-__O generation__O PD__O fluids__O and__O conducted__O clinical__O trials__O to__O assess__O clinical__O outcomes__O such__O as__O residual__O renal__O function,__O risk__O of__O peritonitis,__O and__O fluid__O infusion__O pain.__O
Second-generation__O PD__O fluids__O with__O reduced__O GDP__O content__O were__O produced__O using__O two-compartment__O dialysis__O fluid__O bags,__O which__O separate__O glucose__O from__O buffer__O salts__O during__O heat__O sterilization.__O
Third-generation__O PD__O fluids,__O with__O even__O lower__O GDP__O counts,__O were__O then__O produced__O from__O osmolyte__O that__O is__O resistant__O to__O GDP__O formation,__O such__O as__O icodextrin.__O
All__O of__O the__O major__O companies__O that__O manufacture__O PD__O fluids,__O including__O Baxter__B-ORG Healthcare,__I-ORG Gambro__I-ORG AB,__I-ORG and__O Fresenius__B-ORG Medical__I-ORG Care__I-ORG AG,__I-ORG have__O developed__O and__O marketed__O low-GDP__O solutions,__O and__O Gambro__B-ORG AB__I-ORG now__O produce__O only__O low-GDP__O PD__O fluids.__O
The__O most__O recently__O developed__O PD__B-ORG fluids__O are__O designed__O to__O be__O resistant__O to__O GDP__O formation__O during__O transport__O to__O sites__O of__O use__O and__O storage.__O
Clinical__O benefits__O Clinical__B-PER evidence__O of__O the__O benefits__O of__O low-GDP__O PD__O fluids__O has__O emerged__O since__O 2008b,c,__O including__O data__O to__O show__O improved__O preservation__O of__O residual__O renal__O function__O and__O decreased__O peritonitis,__O fluid__O infusion__O pain,__O and__O vascular__O inflammation.__O
The__O British__B-ORG Renal__I-ORG Society__I-ORG now__O recommends__O that__O all__O patients__O experiencing__O infusion__O pain,__O and__O preferably__O all__O other__O patients__O (provided__O there__O is__O no__O cost__O penalty),__O should__O be__O given__O low-GDP__O PD__O solutions.__O
The__O European__B-ORG Pediatric__I-ORG Dialysis__I-ORG Working__I-ORG Groupd__I-ORG recommends__O low-GDP__O fluid__O use__O in__O all__O paediatric__O patients__O receiving__O PD.__B-ORG
Current__O usage__O of__O low-PD__O fluids__O in__O Europe__B-LOC is__O 60%__O of__O patients__O receiving__O PD__B-ORG dialysis,__O although__O all__O patients__O receiving__O dialysis__O would__O probably__O benefit__O from__O the__O use__O of__O low-GDP__O PD__O fluids.__O
The__O use__O of__O PD__B-ORG therapy__O for__O patients__O with__O renal__O failure__O is__O likely__O to__O increase__O at__O the__O rate__O of__O 5-6%__O per__O annum__O as__O diseases__O linked__O to__O renal__O failure__O become__O more__O prevalent__O and__O access__O to__O dialysis__O improves,__O highlighting__O the__O continued__O importance__O of__O PD__B-ORG fluid__O development.__O
An__O additional__O benefit__O to__O patients__O is__O that__O PD__B-MISC treatment__O with__O low-GDP__O PD__B-ORG fluids__O allows__O PD__B-ORG to__O continue__O for__O longer,__O reducing__O the__O need__O for__O haemodialysis.__O
Economic__O benefits__O The__O total__O global__O market__O for__O PD__B-MISC therapy__O is__O around__O US$2.7__O billion__O per__O year,__O for__O the__O dialysis__O of__O approximately__O 240,000__O patients.__O
The__O use__O of__O low-GDP__O PD__O fluids__O has__O been__O shown__O to__O reduce__O treatment__O costs__O and__O increase__O efficacy.__O
Other__O benefits__O In__O addition__O to__O their__O impact__O on__O PD__O fluid__O composition,__O Thornalley's__B-ORG findings__O led__O the__O food__O industry__O to__O develop__O glyoxalase-1-inducer-based__O foods__O for__O healthy__O ageing__O (Technology__B-ORG Strategy__I-ORG Board__I-ORG project__O with__O Unilever;__B-ORG funding__O &#163;1.1__O million).__O
Selected__O dietary__O bioactive__O compounds__O at__O dietary__O exposure__O levels__O induce__O glyoxalase__O 1__O through__O Nrf2__B-ORG transcriptional__O signalling__O (Xue,__B-PER M.,__I-PER Rabbani,__I-PER N.,__O Momiji,__B-PER H.,__I-PER Imbasi,__I-PER P.,__I-PER Anwar,__I-PER M.__I-PER M.,__I-PER Kitteringham,__I-PER N.__I-PER R.,__I-PER Park,__I-PER B.__I-PER K.,__I-PER Souma,__I-PER T.,__I-PER Moriguchi,__I-PER T.,__I-PER Yamamoto,__I-PER M.__I-PER and__O Thornalley,__B-PER P.__I-PER J.__I-PER
2012__O Transcriptional__O control__O of__O glyoxalase__O 1__O by__O Nrf2__O provides__O a__O stress__O responsive__O defence__O against__O dicarbonyl__O glycation.__O
Biochem.__B-LOC
J.__B-PER
443,__O 213-222).__O
[This__O is__O not__O to__O be__O confused__O with__O certain__O other__O dietary__O bioactive__O compounds__O at__O markedly__O higher__O exposures/doses__O than__O dietary,__O which__O have__O been__O reported__O to__O inhibit__O glyoxalase__O 1__O in__O some__O cell__O model__O systems__O in__O vitro].__O
Other__O research__O from__O Thornalley__O identified__O glyoxalase__O amplification__O in__O multidrug__O resistant__O (MDR)__B-ORG tumours__O and__O sensitivity__O of__O such__O tumours__O to__O glyoxalase__O 1__O inhibitors.__O
This__O led__O pharmaceutical__O companies__O such__O as__O AstraZeneca__B-ORG to__O develop__O glyoxalase__O 1__O inhibitors__O for__O the__O treatment__O of__O multidrug-__O resistant__O tumours.e__O
